Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | poly (ADP-ribose) polymerase 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | poly(ADP-ribose) polymerase catalytic domain-containing protein | 0.018 | 0.5568 | 0.5 |
Echinococcus multilocularis | poly (ADP ribose) polymerase 1 | 0.0174 | 0.5269 | 0.4213 |
Echinococcus granulosus | poly ADP ribose polymerase 1 | 0.0174 | 0.5269 | 0.5269 |
Echinococcus granulosus | metabotropic glutamate receptor 2 | 0.0191 | 0.6046 | 0.6046 |
Brugia malayi | metabotropic glutamate receptor type 2 | 0.0111 | 0.2525 | 0.3107 |
Loa Loa (eye worm) | hypothetical protein | 0.0132 | 0.3444 | 0.3308 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0207 | 0.6732 | 0.8736 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0228 | 0.7677 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0191 | 0.6046 | 0.6141 |
Loa Loa (eye worm) | hypothetical protein | 0.0281 | 1 | 1 |
Trypanosoma cruzi | poly(ADP-ribose) polymerase, putative | 0.0095 | 0.1825 | 0.5 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.0281 | 1 | 1 |
Schistosoma mansoni | poly [ADP-ribose] polymerase | 0.0174 | 0.5269 | 0.5144 |
Trypanosoma cruzi | poly(ADP-ribose) polymerase, putative | 0.0095 | 0.1825 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0095 | 0.1825 | 0.1656 |
Loa Loa (eye worm) | poly(ADP-ribose) polymerase | 0.0068 | 0.0638 | 0.0444 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.026 | 0.9055 | 1 |
Schistosoma mansoni | poly [ADP-ribose] polymerase | 0.0095 | 0.1825 | 0.0727 |
Trypanosoma brucei | poly(adp-ribose) polymerase | 0.0095 | 0.1825 | 0.5 |
Echinococcus multilocularis | metabotropic glutamate receptor 2 | 0.0191 | 0.6046 | 0.5163 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0111 | 0.2525 | 0.1625 |
Loa Loa (eye worm) | glutamate receptor | 0.0228 | 0.7677 | 0.7629 |
Echinococcus granulosus | poly adp ribose polymerase 2 | 0.0095 | 0.1825 | 0.1825 |
Entamoeba histolytica | poly(ADP-ribose) polymerase, putative | 0.0174 | 0.5269 | 0.5 |
Brugia malayi | WGR domain containing protein | 0.0174 | 0.5269 | 0.6778 |
Brugia malayi | WGR domain containing protein | 0.0095 | 0.1825 | 0.217 |
Loa Loa (eye worm) | glutamate receptor | 0.009 | 0.158 | 0.1406 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 31 nM | BindingDB_Patents: Enzyme Assay. A convenient method to determine IC50 of a PARP inhibitor compound is a PARP assay using purified recombinant human PARP from Trevigan (Gaithersburg, Md.), as follows: The PARP enzyme assay is set up on ice in a volume of 100 microliters consisting of 100 mM Tris-HCl (pH 8.0), 1 mM MgCl2, 28 mM KCl, 28 mM NaCl, 3.0 µg/ml of DNase I-activated herring sperm DNA (Sigma, Mo.), 30 micromolar [3H]nicotinamide adenine dinucleotide (62.5 mci/mmole), 15 micrograms/ml PARP enzyme, and various concentrations of the compounds to be tested. The reaction is initiated by adding enzyme and incubating the mixture at 25° C. After 2 minutes of incubation, the reaction is terminated by adding 500 microliters of ice cold 30% (w/v) trichloroacetic acid. The precipitate formed is transferred onto a glass fiber filter (Packard Unifilter-GF/C) and washed three times with 70% ethanol. After the filter is dried, the radioactivity is determined by scintillation counting. | ChEMBL. | No reference |
IC50 (binding) | = 31 nM | Enzyme Assay | BINDINGDB. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.